Me THREE!I can't predict what's going to happen to the share...

Me THREE!

I can't predict what's going to happen to the share price, so I don't even try to play the short term game. Good luck to those who can! What's certain is that, I will not be someone else's exit liquidity at this point.

There aren’t many biotechs as well-positioned as Clarity right now. If AT chooses to go it alone like Telix did - why complain? You’d essentially be getting in on the next Telix, but at an earlier stage and with a suite of proprietary assets. This could be Telix multiplied several times over.

Even if Telix ends up acquiring Clarity, I’d prefer it to be a script-based deal so I can stay invested for the long haul.

Radiopharmaceuticals are on track to become one of the most significant diagnostic and therapeutic breakthroughs in medical history. We shouldn't be surprised? It’s radiation therapy afterall - just made better by precision targeting. What’s even more exciting is that it’s moving into earlier lines of treatment, working alongside or even replacing current standards of care.

Imagine a future where men no longer need prostate removal, or women don’t have to undergo mastectomies - because curative outcomes are possible with targeted radiation. Anything with a targetable receptor, even outside of cancer, becomes fair game for diagnostics in particular.

The "seek and destroy" era is here - and many diseases fit that model perfectly.

---
Clarity has at least TEN COPPER based products in development.

	Product Name	Target	Format	Payload(s)	Indications
1	64Cu-SAR-bisPSMA	PSMA	bis	64Cu	Imaging (prostate cancer)
2	67Cu-SAR-bisPSMA	PSMA	bis	67Cu	Therapy (prostate cancer)
3	64Cu-SAR-bisFAPI	FAP	bis	64Cu	Imaging (pan-cancer)
4	67Cu-SAR-bisFAPI	FAP	bis	67Cu	Therapy (pan-cancer)
5	64Cu-SAR-Bombesin	GRPR	mono	64Cu	Imaging (GRPR-positive cancers)
6	67Cu-SAR-Bombesin	GRPR	mono	67Cu	Therapy (GRPR-positive cancers)
7	64Cu-SARTATE	SSTR2	mono	64Cu	Imaging (neuroblastoma/NETs)
8	67Cu-SARTATE	SSTR2	mono	67Cu	Therapy (neuroblastoma/NETs)
9	64Cu-SAR-trastuzumab	HER2	mono	64Cu	Imaging (HER2+ breast cancer)
10	67Cu-SAR-trastuzumab	HER2	mono	67Cu	Therapy (HER2+ breast cancer)